Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department

被引:37
作者
Brown, Michael D.
Burton, John H.
Nazarian, Devorah J.
Promes, Susan B.
机构
关键词
SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; COMPUTED-TOMOGRAPHY SCORE; COOPERATIVE ACUTE STROKE; SHARED DECISION-MAKING; MIDDLE CEREBRAL-ARTERY; THROMBOLYTIC THERAPY; INTRACRANIAL HEMORRHAGE; ENDOVASCULAR TREATMENT; RT-PA; SAFE IMPLEMENTATION;
D O I
10.1016/j.annemergmed.2015.06.031
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
This clinical policy from the American College of Emergency Physicians is the revision of a clinical policy approved in 2012 addressing critical questions in the evaluation and management of patients with acute ischemic stroke.(1) A writing subcommittee conducted a systematic review of the literature to derive evidence-based recommendations to answer the following clinical questions: (1) Is intravenous tissue plasminogen activator safe and effective for patients with acute ischemic stroke if given within 3 hours of symptom onset? (2) Is intravenous tissue plasminogen activator safe and effective for patients with acute ischemic stroke treated between 3 to 4.5 hours after symptom onset? Evidence was graded and recommendations were made according to the strength of the available data.
引用
收藏
页码:322 / 333
页数:12
相关论文
共 99 条
  • [41] A Graphic Reanalysis of the NINDS Trial
    Hoffman, Jerome R.
    Schriger, David L.
    [J]. ANNALS OF EMERGENCY MEDICINE, 2009, 54 (03) : 329 - 336
  • [42] The Connection Between Evidence-Based Medicine and Shared Decision Making
    Hoffmann, Tammy C.
    Montori, Victor M.
    Del Mar, Chris
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (13): : 1295 - 1296
  • [43] Hoffmann TC, 2014, JAMA INTERN MED, pE1
  • [44] Is Renal Dysfunction Associated with Adverse Stroke Outcome after Thrombolytic Therapy?
    Hsieh, Cheng-Yang
    Lin, Huey-Juan
    Sung, Sheng-Feng
    Hsieh, Han-Chieh
    Lai, Edward Chia-Cheng
    Chen, Chih-Hung
    [J]. CEREBROVASCULAR DISEASES, 2014, 37 (01) : 51 - 56
  • [45] Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Ingall, TJ
    O'Fallon, WM
    Asplund, K
    Goldfrank, LR
    Hertzberg, VS
    Louis, TA
    Christianson, TJH
    [J]. STROKE, 2004, 35 (10) : 2418 - 2424
  • [46] Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
    Jauch, Edward C.
    Saver, Jeffrey L.
    Adams, Harold P., Jr.
    Bruno, Askiel
    Connors, J. J.
    Demaerschalk, Bart M.
    Khatri, Pooja
    McMullan, Paul W., Jr.
    Qureshi, Adnan I.
    Rosenfield, Kenneth
    Scott, Phillip A.
    Summers, Debbie R.
    Wang, David Z.
    Wintermark, Max
    Yonas, Howard
    [J]. STROKE, 2013, 44 (03) : 870 - 947
  • [47] Risk adjustment effect on stroke clinical trials
    Johnston, KC
    Connors, AF
    Wagner, DP
    Haley, EC
    [J]. STROKE, 2004, 35 (02) : E43 - E45
  • [48] Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe
    Karlinski, Michal
    Kobayashi, Adam
    Mikulik, Robert
    Sanak, Daniel
    Wahlgren, Nils
    Czlonkowska, Anna
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (08) : 615 - 622
  • [49] Limitations of applying summary results of clinical trials to individual patients - The need for risk stratification
    Kent, David M.
    Hayward, Rodney A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (10): : 1209 - 1212
  • [50] The stroke-thrombolytic predictive instrument - A predictive instrument for intravenous thrombolysis in acute ischemic stroke
    Kent, David M.
    Selker, Harry P.
    Ruthazer, Robin
    Bluhmki, Erich
    Hacke, Werner
    [J]. STROKE, 2006, 37 (12) : 2957 - 2962